We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Oxurion NV | EU:OXUR | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.001 | 0.41% | 0.243 | 0.243 | 0.267 | 0.2675 | 0.242 | 0.2425 | 66,195 | 16:40:00 |
From Jan 2024 to Jan 2025
Publication Annual Report – Annual Shareholders' Meeting
Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF.
On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to this Meeting have been published in the section “Shareholder Meetings” here.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NVPascal GhosonChief Executive Officerpascal.ghoson@oxurion.com | Backstage CommunicationJurgen VluijmansPartnerjurgen@backstagecom.be |
Attachments
1 Year Oxurion NV Chart |
1 Month Oxurion NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
